Inovio Pharmaceuticals (INO +12.3%) is up on a 4x surge in volume in response to its announced collaboration
with Beijing Advaccine Biotechnology Co. aimed at advancing INO-4800,
its vaccine candidate against 2019-nCoV, the virus causing the current
outbreak.
Inovio is developing INO-4800 through Phase 1 in
the U.S. with the support of an initial $9M grant from the Coalition for
Epidemic Preparedness Innovations (CEPI).
The goal of the partnership with Advaccine is to accelerate development by conducting a parallel Phase 1 study in China.
https://seekingalpha.com/news/3536421-inovio-up-12-on-coronavirus-vaccine-plan
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.